1st published 2019, updated April 2022
MIYOSMART is an optical product invented and designed by Hong Kong Polytechnic University, manufactured by HOYA. It works based on DIMS technology ( Defocus integrated multiple segments). This will create a slight blur at the peripheral view of the lenses (hyperopic defocus, we call it). Hyperopic defocus and has been proven in many clinical research to prevent axial elongation which results in progressing myopia.
Well established products such as Myovision by Zeiss (spectacle lens) , MiSight by Coopervision (contact lenses) works on the same theory. MIYOSMART hyperopic defocus is different from the products mentioned above. It utilizes a honeycomb defocus treatment zone around a 9.1mm clear zone.
When viewing through the lens, the user will feel a slight blur at the edges of your vision. This blur is slight more noticeable than Myovision. However, in a clinical trial, almost of the children adapted to it within 2 weeks. In the same double masked clinical trial, the results are very good. It slowed down myopia progression by 59% and in 21% of the cases, myopia did not increase in the 2 years clinical trial.* Third year results are currently being collected and analysed and will be out soon.
It has been 3 years since we have started prescribing these lenses and as a simple non invasive method, it has done very well. For the treatment to be most effective, the frame selection is very important. The frame has to be well adjusted and fitted to the face. The glasses serves dual function (treatment as well as corrective) and has to be worn full time. We will also recommend a 6 monthly review so that we can stack on low dose atropine to improve the efficacy if required. Miyosmart and atropine are not mutually exclusive and can be used together in a combination therapy if the child does not have extreme photophobia or sluggish accommodation ( rare in low dose atropine, more common in high dose atropine)
We also frequently have request to have blue filter added onto Miyosmart. However, it is currently not available. (to ensure that the lenses used in the research is identical to what is being prescribed). To date, there is no strong evidence that blue light can increase or decrease the rate of myopia.
In summary, Miyosmart is effective in slowing down myopia progression. It can also be used in tandem with low dose atropine for better efficacy if required. Speak to your optometrist.
Link below for full scientific article
https://bjo.bmj.com/content/early/2019/05/29/bjophthalmol-2018-313739
*
Precision Optics @ United Square 